HK1197192A1 - Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 lrrk2 (pet)-18 -11 - Google Patents
Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 lrrk2 (pet)-18 -11Info
- Publication number
- HK1197192A1 HK1197192A1 HK14110821A HK14110821A HK1197192A1 HK 1197192 A1 HK1197192 A1 HK 1197192A1 HK 14110821 A HK14110821 A HK 14110821A HK 14110821 A HK14110821 A HK 14110821A HK 1197192 A1 HK1197192 A1 HK 1197192A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pet
- lrrk2
- fluorine
- imaging
- carbon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161565324P | 2011-11-30 | 2011-11-30 | |
| US201261720870P | 2012-10-31 | 2012-10-31 | |
| PCT/EP2012/073770 WO2013079496A1 (en) | 2011-11-30 | 2012-11-28 | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1197192A1 true HK1197192A1 (en) | 2015-01-09 |
Family
ID=47297200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14110821A HK1197192A1 (en) | 2011-11-30 | 2014-10-29 | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 lrrk2 (pet)-18 -11 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9139566B2 (es) |
| EP (1) | EP2785381B1 (es) |
| JP (1) | JP6148248B2 (es) |
| KR (1) | KR101996699B1 (es) |
| CN (1) | CN104093426B (es) |
| BR (1) | BR112014012822A8 (es) |
| CA (1) | CA2856002C (es) |
| ES (1) | ES2580406T3 (es) |
| HK (1) | HK1197192A1 (es) |
| MX (1) | MX353254B (es) |
| RU (1) | RU2650641C2 (es) |
| WO (1) | WO2013079496A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2576541T1 (sl) * | 2010-06-04 | 2016-07-29 | F. Hoffmann-La Roche Ag | Aminopirimidinski derivati kot modulatorji lrrk2 |
| KR101566091B1 (ko) * | 2010-11-10 | 2015-11-04 | 에프. 호프만-라 로슈 아게 | Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체 |
| AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| MX358172B (es) * | 2012-05-03 | 2018-08-08 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson. |
| RU2016134751A (ru) | 2014-01-29 | 2018-03-02 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
| US10087186B2 (en) * | 2014-01-29 | 2018-10-02 | Glaxosmithkline Intellectual Property Development Limited | Compounds as LRRK2 kinase inhibitors |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| UA126231C2 (uk) | 2016-06-16 | 2022-09-07 | Деналі Терапьютікс Інк. | Піримідин-2-іламіно-1н-піразоли як інгібітори lrrk2 для застосування при лікуванні нейродегенеративних захворювань |
| CN106588884B (zh) * | 2016-11-10 | 2019-04-09 | 浙江大学 | 2-多取代芳环-嘧啶类衍生物及制备和医药用途 |
| WO2018152339A1 (en) * | 2017-02-17 | 2018-08-23 | Yale University | Radiolabeled pharmaceuticals and methods of making and using same |
| CN107827870B (zh) * | 2017-10-24 | 2019-11-08 | 江苏仁明生物科技有限公司 | 一种正电子药物[18f]fpmmp及其制备方法与中间体 |
| JP7284172B2 (ja) | 2017-12-20 | 2023-05-30 | デナリ セラピューティクス インコーポレイテッド | ピリミジニル－４－アミノピラゾール化合物の調製方法 |
| US11530206B2 (en) | 2019-05-10 | 2022-12-20 | Deciphera Pharmaceuticals, Llc | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| RS64755B1 (sr) | 2019-05-10 | 2023-11-30 | Deciphera Pharmaceuticals Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primene |
| KR20220024605A (ko) | 2019-06-17 | 2022-03-03 | 데시페라 파마슈티칼스, 엘엘씨. | 아미노피리미딘 아미드 자가포식 억제제 및 이의 사용 방법 |
| CN111138439B (zh) * | 2020-01-17 | 2021-06-25 | 厦门大学 | 氟代吡咯并嘧啶类化合物及其制备方法和应用 |
| CN111732548B (zh) * | 2020-06-11 | 2022-06-17 | 浙江大学 | N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途 |
| CN111646978B (zh) * | 2020-06-11 | 2021-12-21 | 浙江大学 | N2-取代烷氧芳环-2-氨基嘧啶类衍生物及应用 |
| WO2022084210A1 (en) | 2020-10-20 | 2022-04-28 | F. Hoffmann-La Roche Ag | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors |
| CN115819405A (zh) * | 2022-12-20 | 2023-03-21 | 沪渝人工智能研究院 | 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4448763A (en) * | 1980-11-10 | 1984-05-15 | The University Of Kentucky Research Foundation | Alteration of gallium biodistribution using indium complexes for enhanced early imaging |
| WO2007149789A2 (en) | 2006-06-22 | 2007-12-27 | Applera Corporation | Conversion of target specific amplification to universal sequencing |
| WO2008024826A2 (en) * | 2006-08-23 | 2008-02-28 | Board Of Regents, The University Of Texas System | Radiohalothymidines and methods of their synthesis and use in pet imaging of cancers |
| WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| AR074209A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
| EA021437B1 (ru) | 2009-09-29 | 2015-06-30 | Глэксо Груп Лимитед | Соединения, ингибирующие lrrk2 киназную активность |
| SI2576541T1 (sl) | 2010-06-04 | 2016-07-29 | F. Hoffmann-La Roche Ag | Aminopirimidinski derivati kot modulatorji lrrk2 |
| KR101566091B1 (ko) | 2010-11-10 | 2015-11-04 | 에프. 호프만-라 로슈 아게 | Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체 |
-
2012
- 2012-11-28 CN CN201280058755.6A patent/CN104093426B/zh active Active
- 2012-11-28 JP JP2014543868A patent/JP6148248B2/ja active Active
- 2012-11-28 WO PCT/EP2012/073770 patent/WO2013079496A1/en active Application Filing
- 2012-11-28 MX MX2014006209A patent/MX353254B/es active IP Right Grant
- 2012-11-28 CA CA2856002A patent/CA2856002C/en active Active
- 2012-11-28 RU RU2014125211A patent/RU2650641C2/ru active
- 2012-11-28 ES ES12797828.6T patent/ES2580406T3/es active Active
- 2012-11-28 US US13/687,441 patent/US9139566B2/en active Active
- 2012-11-28 EP EP12797828.6A patent/EP2785381B1/en active Active
- 2012-11-28 BR BR112014012822A patent/BR112014012822A8/pt active Search and Examination
- 2012-11-28 KR KR1020147017567A patent/KR101996699B1/ko active IP Right Grant
-
2014
- 2014-10-29 HK HK14110821A patent/HK1197192A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX353254B (es) | 2018-01-05 |
| JP2015500216A (ja) | 2015-01-05 |
| RU2014125211A (ru) | 2016-01-27 |
| CN104093426A (zh) | 2014-10-08 |
| EP2785381A1 (en) | 2014-10-08 |
| BR112014012822A8 (pt) | 2017-07-11 |
| WO2013079496A1 (en) | 2013-06-06 |
| EP2785381B1 (en) | 2016-05-18 |
| KR101996699B1 (ko) | 2019-07-04 |
| JP6148248B2 (ja) | 2017-06-14 |
| KR20140097470A (ko) | 2014-08-06 |
| RU2650641C2 (ru) | 2018-04-16 |
| CA2856002A1 (en) | 2013-06-06 |
| CN104093426B (zh) | 2019-06-28 |
| CA2856002C (en) | 2020-10-13 |
| BR112014012822A2 (pt) | 2017-06-13 |
| US9139566B2 (en) | 2015-09-22 |
| MX2014006209A (es) | 2014-08-08 |
| US20130156700A1 (en) | 2013-06-20 |
| ES2580406T3 (es) | 2016-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1197192A1 (en) | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 lrrk2 (pet)-18 -11 | |
| EP2739210A4 (en) | RADIATION IMAGING SYSTEM | |
| AP2014008056A0 (en) | D-amino acid compounds for liver disease | |
| EP2531105A4 (en) | RADIATION IMAGING SYSTEM | |
| LT2997901T (lt) | Vaizdo gavimo zondas | |
| EP2731488A4 (en) | INTRAORAL IMAGING SYSTEM | |
| EP2799911A4 (en) | RADIATION DETECTOR | |
| GB201102614D0 (en) | Material identification using multiple images | |
| EP2672292A4 (en) | RADIATION SENSOR | |
| PL2928505T3 (pl) | Peptydy znakowane radionuklidem emitującym pozyton do obrazowania pet upar u ludzi | |
| ZA201308188B (en) | Radiolabeled amino acids for diagnostic imaging | |
| EP2769675A4 (en) | PROGRAM AND SYSTEM FOR DYNAMIC RADIOGRAPHIC IMAGING | |
| GB2481090B (en) | Thermal imaging camera | |
| EP2759538A4 (en) | WITH RADIOACTIVE FLUOR MARKED CONNECTION | |
| PL2628146T3 (pl) | Nowy sposób obrazowania przy wykorzystaniu promieniowań przenikliwych | |
| GB201020314D0 (en) | Apoptosis pet imaging agents | |
| GB2493844B (en) | Radiation detector | |
| EP2775923A4 (en) | SYSTEMS AND METHODS FOR SIMULTANEOUS MULTI-DIRECTIONAL IMAGING FOR CAPTURING TOMOGRAPHIC DATA | |
| EP2708188A4 (en) | X-RAY IMAGING APPARATUS | |
| EP2715448A4 (en) | IMAGING SYSTEM | |
| EP2662021A4 (en) | X-RAY CT SCANNER | |
| DK2734834T3 (da) | Røntgenbilleddannelse | |
| GB2501891B (en) | Radiography imaging system | |
| EP2826068A4 (en) | X-MATRIX DISPLAY | |
| EP2739993A4 (en) | RADIOLOGICAL IMAGE SENSOR |